TUSC2 nanovesicles combined with erlotinib, an inhibitor of activated epidermal growth factor (EGFR), synergistically inhibited tumor growth and metastases in NSCLC cells with wildtype EGFR by abrogating resistance pathways related to FGFR2 and mTOR activation6. Here, TUSC2 is linked to neoplasm.